Claims

1. An aqueous pharmaceutical composition for injection comprising
a) from 0.1 mg/mL to 60 mg/mL methyl (2R.3R)-2-{3-[amino(imino) methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate,
b) from 1 mMol/L to 1000 mMol/L acidic reacting compound or its salt or a mixture thereof and
c) is adjusted to a pH from about pH 3 to about pH 5.0 by addition of said acidic reacting compound.

2. The pharmaceutical composition according to claim 1 wherein said acidic reacting compound is selected from the group consisting of citric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, ascorbic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicyclic acid, 2-phenoxybenzoic acid, p-toluenesulfonic acid, methanesulfonic acid, 2-hydroxyethanesulfonic acid, hyaluronic acid, acetyl salicylic acid or amino acids or mineral acids selected from the group consisting of hydrochloride acid or phosphoric acid or salts of said organic acids, amino acids and mineral acids or a mixture of one or more of said acidic reacting compounds.

3. The pharmaceutical composition according to claim 2 wherein said acidic reacting compound is selected from citric acid and sodium citrate or a mixture thereof.

4. The aqueous pharmaceutical composition according to claims 1 to 3 comprising from 1.0 mg/mL to 50 mg/mL methyl (2R.3R)-2-{3-[amino(imino) methyl]benzyl}- 3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate, and
from 20 mMol to 25 mMol acidic reacting compound or its salt or a mixture thereof.

13. The pharmaceutical composition according to claims 1 to 12, wherein said pharmaceutical composition is sterile.

14. The pharmaceutical composition according to claims 1 to 13 for use in the treatment of acute myocardial infarction, non-ST elevation myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy, percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, intermittent claudication, and restenosis.

15. Use of the pharmaceutical composition according to claims 1 to 13 in the manufacture of a medicament for the treatment of acute myocardial infarction, non-ST elevation myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy, percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, intermittent claudication, or restenosis.